Marcelo C Pasquini

List of Publications by Year
in descending order

212	14,415	36203	21474
papers	citations	51 h-index	114 g-index

215	215	215	12157
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. American Journal of Hematology, 2023, 98, 140-147.	2.0	12
2	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.	1.7	87
3	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood, 2022, 139, 1330-1339.	0.6	52
4	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Advances, 2022, 6, 486-494.	2.5	25
5	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2022, 40, 356-368.	0.8	79
6	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer Journal, 2022, 12, 27.	2.8	19
7	Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. Cytotherapy, 2022, 24, 742-749.	0.3	2
8	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	0.6	11
9	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology, 2022, 197, 326-338.	1.2	1
10	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplantation and Cellular Therapy, 2022, 28, 409.e1-409.e10.	0.6	26
11	Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. Leukemia and Lymphoma, 2022, 63, 2507-2510.	0.6	4
12	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplantation and Cellular Therapy, 2022, 28, 581.e1-581.e8.	0.6	61
13	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine, 2022, 387, 132-147.	13.9	173
14	Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.. Journal of Clinical Oncology, 2022, 40, 7571-7571.	0.8	6
15	Lenalidomide, bortezomib, and dexamethasone (RVd) Â± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.. Journal of Clinical Oncology, 2022, 40, LBA4-LBA4.	0.8	3
16	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	3.3	69
17	Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO Precision Oncology, 2021, 5, 265-274.	1.5	13
18	Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromesâ€”Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplantation and Cellular Therapy, 2021, 27, 483.e1-483.e6.	0.6	52

#	Article	IF	Citations
19	The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).. Journal of Clinical Oncology, 2021, 39, 7003-7003.	0.8	2
20	Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. Journal of Clinical Oncology, 2021, 39, 7552-7552.	0.8	5
21	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	0.6	13
22	Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Frontiers in Genetics, 2021, 12, 554948.	1.1	8
23	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Advances, 2021, 5, 2519-2522.	2.5	10
24	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Journal of Clinical Oncology, 2021, 39, 1865-1877.	0.8	111
25	Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. Scientific Reports, 2021, 11, 15004.	1.6	4
26	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplantation and Cellular Therapy, 2021, 27, 885-907.	0.6	12
27	Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation. EClinicalMedicine, 2021, 40, 101093.	3.2	8
28	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 807-816.	0.6	3
29	Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients postâ€“unrelated HCT. Blood Advances, 2021, 5, 66-70.	2.5	6
30	Beyond the storm â€” subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	12.5	37
31	The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Translational Psychiatry, 2021, 11, 58.	2.4	36
32	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients. Hematology, Transfusion and Cell Therapy, 2021, 43, S30-S34.	0.1	1
33	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood, 2021, 138, 429-429.	0.6	9
34	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood, 2021, 138, 530-530.	0.6	9
35	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e7-e15.	2.0	16
36	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 131-142.	0.6	14

#	Article	IF	Citations
37	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biology of Blood and Marrow Transplantation, 2020, 26, 333-342.	2.0	30
38	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 798-804.	2.0	28
39	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. Biology of Blood and Marrow Transplantation, 2020, 26, e77-e85.	2.0	41
40	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. Journal of Clinical Oncology, 2020, 38, 1273-1283.	0.8	281
41	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2229-2236.	2.0	4
42	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 2011-2017.	2.0	11
43	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biology of Blood and Marrow Transplantation, 2020, 26, 2181-2189.	2.0	51
44	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biology of Blood and Marrow Transplantation, 2020, 26, 2372-2377.	2.0	19
45	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1876-1885.	2.0	4
46	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Advances, 2020, 4, 2810-2820.	2.5	47
47	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Advances, 2020, 4, 5414-5424.	2.5	263
48	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, e161-e166.	2.0	38
49	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. Blood, 2020, 136, 137-139.	0.6	51
50	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.		7
51	Incidence, Risk Factors for and Outcomes of Transplantâ€Associated Thrombotic Microangiopathy. British Journal of Haematology, 2020, 189, 1171-1181.	1.2	58
52	Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. Biology of Blood and Marrow Transplantation, 2020, 26, e138-e141.	2.0	8
53	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biology of Blood and Marrow Transplantation, 2020, 26, 1288-1297.	2.0	10
54	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1670-1678.	2.0	17

#	Article	IF	Citations
55	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
56	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biology of Blood and Marrow Transplantation, 2020, 26, 893-901.	2.0	13
57	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Advances, 2020, 4, 467-476.	2.5	39
58	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation, 2020, 26, e177-e182.	2.0	378
59	Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation. Blood, 2020, 136, 34-35.	0.6	3
60	Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. Journal of Clinical Oncology, 2020, 38, 8506-8506.	0.8	63
61	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2020, 136, 7-8.	0.6	0
62	Associations of Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation with Number of Predicted Class II Restricted mHA. Blood, 2020, 136, 2-2.	0.6	0
63	Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 7-8.	0.6	0
64	Pre-Transplant Clonal Mosaicism Is Associated with Increased Relapse and Lower Survival in Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplant. Blood, 2020, 136, 9-10.	0.6	0
65	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplantation, 2019, 54, 402-417.	1.3	31
66	Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 87-88.	1.4	2
67	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 56.	2.8	15
68	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Network Open, 2019, 2, e196476.	2.8	12
69	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Biology of Blood and Marrow Transplantation, 2019, 25, 1890-1897.	2.0	19
70	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407.	2.0	21
71	Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2024-2030.	2.0	33
72	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation, 2019, 25, 2322-2329.	2.0	21

#	Article	IF	Citations
73	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biology of Blood and Marrow Transplantation, 2019, 25, 2330-2337.	2.0	22
74	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatrics, 2019, 173, e190081.	3.3	14
75	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1456-1464.	2.0	18
76	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. Biology of Blood and Marrow Transplantation, 2019, 25, 1424-1431.	2.0	14
77	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq1 1 0.784314 rgBT /Overlo methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	2.2	200
78	Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1689-1694.	2.0	70
79	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 1492-1497.	2.0	23
80	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. Journal of Clinical Oncology, 2019, 37, 589-597.	0.8	184
81	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 845-854.	2.0	69
82	â€œWorldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registriesâ€• Bone Marrow Transplantation, 2019, 54, 1179-1188.	1.3	51
83	Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT. Blood Advances, 2019, 3, 2337-2341.	2.5	8
84	Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. Blood Advances, 2019, 3, 2512-2524.	2.5	7
85	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 827-833.	2.0	23
86	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
87	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2019, 25, e89-e97.	2.0	12
88	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
89	Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up. Blood, 2019, 134, 259-259.	0.6	2
90	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. Blood, 2019, 134, 700-700.	0.6	3

#	Article	IF	Citations
91	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood, 2019, 134, 764-764.	0.6	77
92	Real World Data on CAR T-Cell Recipients: Are We There Yet?. , 2019, 16, .		2
93	The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study. Blood, 2019, 134, 412-412.	0.6	0
94	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- versus -host disease: low incidence of lower gastrointestinal tract disease. Haematologica, 2018, 103, 717-727.	1.7	38
95	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplantation, 2018, 53, 1210-1213.	1.3	7
96	Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood, 2018, 131, 2490-2499.	0.6	21
97	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer, 2018, 124, 1733-1742.	2.0	58
98	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 983-988.	2.0	5
99	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biology of Blood and Marrow Transplantation, 2018, 24, 1274-1280.	2.0	46
100	Peripheral Blood Grafts for T Cellâ€“Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 1664-1670.	2.0	36
101	Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 105-111.	0.6	7
102	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2018, 24, 641-648.	2.0	19
103	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Advances, 2018, 2, 1198-1206.	2.5	21
104	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1961-1964.	2.0	47
105	Pharmacokinetics of High-Dose Propylene Glycolâ€“Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1610-1614.	2.0	8
106	Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma. Cancer, 2018, 124, 3455-3456.	2.0	0
107	Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, 2072-2080.	2.0	50
108	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. Blood, 2018, 132, 1015-1015.	0.6	2

#	Article	IF	Citations
109	Genome Wide Association Analyses Identify Pleiotropic Variants Associated with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Susceptibility. Blood, 2018, 132, 1500-1500.	0.6	0
110	Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	0.6	0
111	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. Blood, 2018, 132, 3544-3544.	0.6	0
112	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. Blood, 2018, 132, 617-617.	0.6	0
113	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2018, 132, 1998-1998.	0.6	0
114	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Clinical Oncology, 2017, 35, 1154-1161.	0.8	495
115	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2017, 74, 459.	4.5	199
116	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1295-1302.	2.0	8
117	Current Use and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation, 2017, 23, 1417-1421.	2.0	205
118	Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 952-957.	2.0	18
119	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	2.2	132
120	Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood, 2017, 130, 1585-1596.	0.6	45
121	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemporary Clinical Trials Communications, 2017, 8, 33-38.	0.5	17
122	Alphaâ€1â€antitrypsin for the treatment of steroidâ€refractory acute gastrointestinal graftâ€versusâ€host disease. American Journal of Hematology, 2017, 92, E610-E611.	2.0	7
123	Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 167-172.	0.6	27
124	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 1955-1960.	2.0	24
125	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	0.6	210
126	Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a <scp>BMT CTN</scp> 0102 correlative study. British Journal of Haematology, 2017, 178, 816-819.	1.2	4

#	Article	IF	Citations
127	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
128	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. Blood Advances, 2017, 1, 1717-1728.	2.5	15
129	Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.. Journal of Clinical Oncology, 2017, 35, 7062-7062.	0.8	0
130	Response status as predictor of survival after autologous hematopoietic cell transplant (AHCT), without or with consolidation (with bortezomib, lenalidomide (Len) and dexamethasone) and len maintenance (AM vs. ACM) versus tandem AHCT and len maintenance (TAM) for up-front treatment of patients (pts) with multiple myeloma (MM): BMT CTN0702-stamina (NCT01109004).. Journal of Clinical Oncology, 2017, 35, 8010-8010.	0.8	0
131	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. Journal of Clinical Oncology, 2017, 35, 8012-8012.	0.8	0
132	Allogeneic stem cell transplant (AHCT) in the eighth decade: Age is just a number.. Journal of Clinical Oncology, 2017, 35, 7045-7045.	0.8	0
133	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2016, 101, 1426-1433.	1.7	53
134	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood, 2016, 128, 2450-2456.	0.6	32
135	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 379-386.	0.2	17
136	Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 1424-1430.	2.0	18
137	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation, 2016, 22, 1197-1205.	2.0	17
138	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1773-1780.	2.0	7
139	Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology. American Journal of Hematology, 2016, 91, 787-792.	2.0	8
140	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
141	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biology of Blood and Marrow Transplantation, 2016, 22, 744-751.	2.0	41
142	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biology of Blood and Marrow Transplantation, 2016, 22, 932-940.	2.0	43
143	Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial). Blood, 2016, 128, LBA-1-LBA-1.	0.6	52
144	Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL). Blood, 2016, 128, 5192-5192.	0.6	0

#	Article	IF	Citations
145	Replication of Candidate SNP Survival Analyses and Gene-Based Tests of Association with Survival Outcomes after an Unrelated Donor Blood or Marrow Transplant: Results from the Discovery-BMT Study. Blood, 2016, 128, 71-71.	0.6	0
146	Exome Array Analyses Identify New Genes Influencing Survival Outcomes after HLA-Matched Unrelated Donor Blood and Marrow Transplantation. Blood, 2016, 128, 518-518.	0.6	0
147	Exome Array Analyses Identify Low-Frequency Germline Variants Associated with Increased Risk of AML in a HLA-Matched Unrelated Donor Blood and Marrow Transplant Population. Blood, 2016, 128, 42-42.	0.6	0
148	Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?. Current Hematologic Malignancy Reports, 2015, 10, 45-58.	1.2	11
149	One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematology,the, 2015, 2, e91-e100.	2.2	329
150	The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1251-1257.	2.0	14
151	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1479-1487.	2.0	173
152	Guidelines for Defining and Implementing Standard Episode of Care for Hematopoietic Stem Cell Transplantation within the Context of Clinical Trials. Biology of Blood and Marrow Transplantation, 2015, 21, 583-588.	2.0	18
153	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. Biology of Blood and Marrow Transplantation, 2015, 21, 761-767.	2.0	195
154	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1046-1053.	2.0	133
155	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
156	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1679-1686.	2.0	37
157	Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biology of Blood and Marrow Transplantation, 2015, 21, 4-7.	2.0	83
158	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Blood, 2015, 126, LBA-8-LBA-8.	0.6	59
159	A statistical model for predicting neutropenic fever.. Journal of Clinical Oncology, 2015, 33, e18050-e18050.	0.8	0
160	Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies.. Journal of Clinical Oncology, 2015, 33, 7033-7033.	0.8	0
161	Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study). Blood, 2015, 126, 61-61.	0.6	7
162	Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML). Blood, 2015, 126, 4954-4954.	0.6	0

#	Article	IF	Citations
163	Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts. Blood, 2015, 126, 4492-4492.	0.6	0
164	Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT). Blood, 2015, 126, 2621-2621.	0.6	5
165	Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study). Blood, 2015, 126, 397-397.	0.6	1
166	Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2015, 126, 198-198.	0.6	0
167	Five hematologic tests and treatments to question. Hematology American Society of Hematology Education Program, 2014, 2014, 599-603.	0.9	9
168	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1183-1189.	2.0	89
169	Plerixafor and Abbreviated-Course Granulocyte Colonyâ€“Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2014, 20, 1926-1931.	2.0	23
170	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2014, 20, 402-408.e1.	2.0	98
171	Acute graft-versus-host disease: a bench-to-bedside update. Blood, 2014, 124, 363-373.	0.6	178
172	Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood, 2014, 123, 3504-3511.	0.6	31
173	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood, 2014, 124, 1372-1377.	0.6	178
174	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood, 2014, 124, 3221-3227.	0.6	92
175	Five hematologic tests and treatments to question. Blood, 2014, 124, 3524-3528.	0.6	50
176	Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts. Blood, 2014, 124, 319-319.	0.6	6
177	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). Blood, 2014, 124, 422-422.	0.6	6
178	A Statistical Model for Predicting Neutropenic Fever. Blood, 2014, 124, 5258-5258.	0.6	0
179	A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality. Blood, 2014, 124, 188-188.	0.6	147
180	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica, 2013, 98, 1282-1290.	1.7	110

#	Article	IF	Citations
181	Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood, 2013, 122, 3871-3878.	0.6	141
182	2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clinical Transplants, 2013, , 187-97.	0.2	34
183	Hematopoietic cell transplantation in Latin America. Hematology, 2012, 17, s189-s191.	0.7	13
184	Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology, 2012, 17, s79-s82.	0.7	10
185	Comparative Outcomes of Donor Graft CD34⁺ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2012, 30, 3194-3201.	0.8	143
186	Characteristics of CliniMACSÂ® System CD34-Enriched TÂCell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. Biology of Blood and Marrow Transplantation, 2012, 18, 690-697.	2.0	63
187	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1471-1478.	2.0	62
188	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1770-1781.	13.9	1,024
189	Global Trends in Hematopoietic Cell Transplantation.. Blood, 2012, 120, 3143-3143.	0.6	2
190	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2012, 120, 733-733.	0.6	4
191	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. Blood, 2012, 120, 739-739.	0.6	19
192	The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases. Blood, 2012, 120, 737-737.	0.6	11
193	Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2011, 17, 737-744.	2.0	25
194	Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cellâ€“Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303. Biology of Blood and Marrow Transplantation, 2011, 17, 1343-1351.	2.0	135
195	Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?. Journal of Clinical Oncology, 2011, 29, 805-813.	0.8	178
196	Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays â€“ Comparison with Electrophoretic Responses in Multiple Myeloma (MM). Blood, 2011, 118, 2877-2877.	0.6	4
197	Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap. Blood, 2011, 118, 1016-1016.	0.6	1
198	Hematopoietic Stem Cell Transplantation<subtitle>A Global Perspective</subtitle>. JAMA - Journal of the American Medical Association, 2010, 303, 1617.	3.8	556

#	Article	IF	Citations
199	Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. Biology of Blood and Marrow Transplantation, 2010, 16, 1076-1083.	2.0	46
200	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults. Biology of Blood and Marrow Transplantation, 2010, 16, 1442-1450.	2.0	64
201	Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. Blood, 2010, 116, 3486-3486.	0.6	2
202	Transplant Conditioning Regimens and Outcomes After Allogeneic Hematopoietic Cell Transplantation (HCT) In Children and Adolescents with Acute Lymphoblastic Leukemia (ALL). Blood, 2010, 116, 3506-3506.	0.6	1
203	Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Blood, 2010, 116, 41-41.	0.6	14
204	Tandem Autologous Stem Cell Transplants (auto-auto) with or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial. Blood, 2010, 116, 526-526.	0.6	7
205	Defining the Intensity of Conditioning Regimens: Working Definitions. Biology of Blood and Marrow Transplantation, 2009, 15, 1628-1633.	2.0	1,419
206	HLA-Identical Sibling-Matched, CD34+ Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.. Blood, 2009, 114, 655-655.	0.6	4
207	HLA-Matched Sibling Hematopoietic Stem Cell Transplantation for Fanconi Anemia: Comparison of Irradiation and Nonirradiation Containing Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2008, 14, 1141-1147.	2.0	69
208	Risk Factors and Outcome after Second HLA-Matched Sibling Donor Transplantation for Graft Failure after a First HLA-Matched Sibling Transplant in Severe Aplastic Anemia.. Blood, 2007, 110, 1110-1110.	0.6	0
209	Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor.. Blood, 2007, 110, 3028-3028.	0.6	1
210	The Likelihood of Hematopoietic Stem Cell Transplantation (HCT) in the United States: Implications for Umbilical Cord Blood Storage.. Blood, 2005, 106, 1330-1330.	0.6	4
211	Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 1138-1138.	0.6	0
212	Autologous hematopoietic cell transplants for autoimmune diseases: Therapeutic rationale and limitations. , 0, , 531-534.		0